医学
糖尿病
内科学
2型糖尿病
血压
内分泌学
胰岛素抵抗
噻嗪
高血压的病理生理学
肾素-血管紧张素系统
利尿剂
作者
Ele Ferrannini,William C. Cushman
出处
期刊:The Lancet
[Elsevier BV]
日期:2012-08-01
卷期号:380 (9841): 601-610
被引量:632
标识
DOI:10.1016/s0140-6736(12)60987-8
摘要
High blood pressure is reported in over two-thirds of patients with type 2 diabetes, and its development coincides with the development of hyperglycaemia. Many pathophysiological mechanisms underlie this association. Of these mechanisms, insulin resistance in the nitric-oxide pathway; the stimulatory effect of hyperinsulinaemia on sympathetic drive, smooth muscle growth, and sodium–fluid retention; and the excitatory effect of hyperglycaemia on the renin–angiotensin–aldosterone system seem to be plausible. In patients with diabetes, hypertension confers an enhanced risk of cardiovascular disease. A blood pressure of lower than 140/85 mm Hg is a reasonable therapeutic goal in patients with type 2 diabetes according to clinical trial evidence. People with controlled diabetes have a similar cardiovascular risk to patients without diabetes but with hypertension. A renin–angiotensin system blocker combined with a thiazide-type diuretic might be the best initial antihypertensive regimen for most people with diabetes. In general, the positive effects of antihypertensive drugs on cardiovascular outcomes outweigh the negative effects of antihypertensive drugs on glucose metabolism.
科研通智能强力驱动
Strongly Powered by AbleSci AI